A Multicenter, Single-blind, Randomized, Controlled Study to Evaluate the Efficacy and Safety of JT001 (VV116) Compared With Paxlovid for the Early Treatment of COVID-19 in Participants With Mild to Moderate COVID-19

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deuremidevir hydrobromide (Primary) ; Nirmatrelvir+ritonavir
Indications COVID 2019 infections
Focus Registrational; Therapeutic Use
Sponsors Vigonvita Life Sciences

Most Recent Events

10 Jan 2025 According to the Shanghai Junshi Biosciences Impact Therapeutics (JV) media release, data from this study published in the international authoritative journal The New England Journal of Medicine.
10 Jan 2025 Results published in a Shanghai Junshi Biosciences Impact Therapeutics (JV) media release.
29 Dec 2022 Results published in a Shanghai Junshi Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight